Month: September 2023

Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary...

Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023

PALO ALTO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating...

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

Caren Deardorf Editas Medicine, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer.CAMBRIDGE,...

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed...

TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138

Further Supports TTX-MC138 Application in Brain CancerBOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA...

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections

Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence

Collaboration will apply Valo’s Opal Computational Platform™ and real-world patient dataset to enable the discovery and development of novel cardiometabolic...

PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101

error: Content is protected !!